Literature DB >> 9455925

Temperature differences for trans-glycosylation and hydrolysis reaction reveal an acceptor binding site in the catalytic mechanism of Trypanosoma cruzi trans-sialidase.

M Ribeirão1, V L Pereira-Chioccola, D Eichinger, M M Rodrigues, S Schenkman.   

Abstract

Trypanosoma cruzi, the agent of Chagas disease, expresses on its surface a trans-sialidase that catalyzes preferentially the transference of alpha-2,3-linked sialic acid to acceptors containing terminal beta-galactosyl residues, instead of the typical hydrolysis reaction, found in most sialidases. The trans-sialidase is responsible for the acquisition of the host sialic acid by this protozoan parasite, which does not synthesize sialic acids. Here, we have studied some kinetic properties of a recombinant trans-sialidase expressed in Escherichia coli. We found that it has sequential-type kinetics for the transferase reaction, as shown for the parasite-derived enzyme. The rates of sialic acid transfer to water (hydrolysis), and to beta-galactosyl residues have a unique behavior with respect to the reaction temperature. While the hydrolysis rate of sialyllactose increases continuously up to 35 degrees C, the temperature for the maximal rate of trans-glycosylation depends on the acceptor concentration. At low acceptor concentrations the rate of trans-glycosylation is maximal at 13 degrees C and independent of the amount of sialic acid donors. With increasing acceptor concentrations, maximal rates of trans-glycosylation are shifted to higher temperatures. This finding is explained by an 8-fold increase in the Km for the acceptor from 13 degrees C to 33 degrees C. Differences in hydrolysis and transfer rates were also obtained by using 4-methylumbelliferyl-N-acetyl-neuraminic acid. However, its hydrolysis rate is much higher than the rate of transference to lactose, suggesting that a long-lived enzyme-sialosyl intermediate is not formed. In addition, lactose does not increase the rate of methyl-umbelliferone release at any temperature, indicating that the rate limiting step is the aglycon release. Based on these results we propose that transglycosylation in T. cruzi sialidase is favored by the existence of a binding site for beta-galactosyl residues, which accepts the new glycosidic bond as sialic acid is released from the donor. With increasing temperature the affinity for the acceptor decreases, resulting in a concomitant increase in the rate of transfer to water, which, in turn, can be suppressed by increasing the acceptor concentration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9455925     DOI: 10.1093/glycob/7.8.1237

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  15 in total

1.  Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.

Authors:  Vera Lucia Pereira-Chioccola; Abilio Augusto Fragata-Filho; Antonio Marcos de Apparecida Levy; Mauricio M Rodrigues; Sergio Schenkman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

2.  Continuous nonradioactive method for screening trypanosomal trans-sialidase activity and its inhibitors.

Authors:  Paula A Sartor; Rosalía Agusti; Maria S Leguizamón; Oscar Campetella; Rosa M de Lederkremer
Journal:  Glycobiology       Date:  2010-04-07       Impact factor: 4.313

3.  Evidence of ternary complex formation in Trypanosoma cruzi trans-sialidase catalysis.

Authors:  Isadora A Oliveira; Arlan S Gonçalves; Jorge L Neves; Mark von Itzstein; Adriane R Todeschini
Journal:  J Biol Chem       Date:  2013-11-05       Impact factor: 5.157

4.  Galactosyl-lactose sialylation using Trypanosoma cruzi trans-sialidase as the biocatalyst and bovine κ-casein-derived glycomacropeptide as the donor substrate.

Authors:  Maarten H Wilbrink; Geert A ten Kate; Sander S van Leeuwen; Peter Sanders; Erik Sallomons; Johannes A Hage; Lubbert Dijkhuizen; Johannis P Kamerling
Journal:  Appl Environ Microbiol       Date:  2014-07-25       Impact factor: 4.792

5.  Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.

Authors:  Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

6.  DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene.

Authors:  A E Fujimura; S S Kinoshita; V L Pereira-Chioccola; M M Rodrigues
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

7.  Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.

Authors:  M M Rodrigues; M Ribeirão; V Pereira-Chioccola; L Renia; F Costa
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

8.  Induction of proinflammatory cytokines and nitric oxide by Trypanosoma cruzi in renal cells.

Authors:  Gabriel M de Oliveira; Nobuko Yoshida; Elisa M S Higa; Sérgio Shenkman; Monique Alves; Daniela Staquicini; Cynthia Cascabulho; Nestor Schor
Journal:  Parasitol Res       Date:  2011-02-17       Impact factor: 2.289

9.  Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.

Authors:  Fredj Ben Bdira; Marta Artola; Herman S Overkleeft; Marcellus Ubbink; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2018-10-02       Impact factor: 5.922

10.  Trans-sialidase activity of Photobacterium damsela alpha2,6-sialyltransferase and its application in the synthesis of sialosides.

Authors:  Jiansong Cheng; Shengshu Huang; Hai Yu; Yanhong Li; Kam Lau; Xi Chen
Journal:  Glycobiology       Date:  2009-10-30       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.